Escalating immunotherapy of multiple sclerosis: New aspects and practical application

Journal of Neurology

Volumn 251, Issue 11, 2004, Pages 1329-1339

  Rieckmann, P ^a   Toyka, K V ^a  

^a Dept of Neurology ^*  (Germany)

Author keywords

Consensus; Immunotherapy; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLATIRAMER; GLUCOCORTICOID; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; RECOMBINANT BETA INTERFERON;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; HEALTH PRACTITIONER; HUMAN; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INFLAMMATION; LEUKEMIA; LONG TERM CARE; META ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SIDE EFFECT; TREATMENT FAILURE;

CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERFERON-BETA; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; TREATMENT OUTCOME;

EID: 12744261338     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-0537-6     Document Type: Review

References (57)

1. Barkhof F, Filippi M, Miller D, Scheltens P, Campi A, Polman C, et al. (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059-2069
2. Bashir K, Buchwald L, Coyle P, Freedman M, Jeffery D, Markowitz C, et al. (2002) Optimizing immunomodulatory therapy for MS patients. Int J MS Care 8:3-7
3. Brex PA, Jenkins R, Fox NC, Crum WR, O'Riordan JI, Plant GT, et al. (2000) Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54:1689-1691
4. CHAMPS Study Group (2002) MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 59:998-1005
5. Clanet M, Radue E, Kappos L, Hartung H, Hohlfeld R, Sandberg-Wollheim M, et al. (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59:1507-1517
6. Cohen J, Cutter G, Fischer J, Goodman A, Heidenreich F, Kooijmans M, et al. (2002) Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59:679-687
7. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357: 1576-1582
8. Comi G, Filippi M, Wolinsky J, et al. (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 49:290-297
9. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O (2002) Effect of early interferon treatment on conversion to definite multiple sclerosis: The ETOMS study-4 years results. Mult Scler 8(Suppl. 1):S8
10. Dalton C, Brex P, Miszkiel K, et al. (2002) Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 52:47-53
11. Delisse B, et al. (2004) Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. Mult Scler 10:92
12. De Stefano N, Narayanan S, Francis G, et al. (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58:65-70
13. Durelli L, Verdun E, Barero P, et al. (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). TLancet 359:1453-1460
14. European Study Group on Interferon beta-1b in Secondary Progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352: 1491-1497
15. Fazekas F, Barkhof F, Filippi M, et al. (1999) The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 53: 448-456
16. Filippini G, Munari L, Incorvaia B, et al. (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361:545-552
17. Ghalie R, Edan G, Laurent M, et al. (2002) Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59:909-913
18. Ghalie R, Mauch E, Edan G, et al. (2002) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 8: 441-445
19. Gold R, Buttgereit F, Toyka K (2001) Mechanism of action of glucocorticoid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 117:1-8
20. Goodin D, Frohman E, Garmany G, et al. (2002) Disease modifying therapies in multiple sclerosis - Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology 58:169-178
21. Hartung H, Gonsette R, König N, et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360: 2018-2025
22. Jacobs LD, Beck RW, Simon JH, et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898-904
23. Johnson K, Brooks B, Ford C, et al. (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 6:255-266
24. Keegan M, Pineda A, McClelland R, Darby C, Rodriguez M, Weinshenker B (2002) Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58: 143-146
25. Khan O, Tselis A, Kamholz J, Garbern J, Lewis R, Lisak R (2001) A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFN-beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 7:349-353
26. La Mantia L, et al. (2002) Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev. 4: CD002819
27. Leary S, Miller D, Stevenson V, Brex P, Chard D, Thompson A (2003) Interferon beta-1a in primary progressive MS. Neurology 60:44-51
28. Li D, Zhao G, Paty D, et al. (2001) Randomized controlled trial of interferon-beta 1a in secondary progressive MS. Neurology 56:1505-1513
29. Lublin FD, Baier M, Cutter G (2003) Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61:1528-1532
30. McDonald W, Compston A, Edan G, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
31. Miller D, Khan O, Sheremata W, et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15-23
32. MS-Therapie Konsensus Gruppe - MSTKG (1999) Immunmodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt 70:371-386
33. National Multiple Sclerosis Society - NMSS (1998) Disease management consensus statement. Internet: www.nmss.org
34. Noseworthy J, O'Brien P, Weinshenker B, et al. (2000) IV immunoglobulin does not reverse established weakness in MS. Neurology 55:1135-1143
35. Noseworthy J, O'Brien P, Petterson T, et al. (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56:1514-1522
36. Oger J, Freedman M, et al. (1999) Consensus statement of the Canadian MS clinics network on the use of disease modifying agents in mutiple sclerosis. Can J Neurol Sci 26:294
37. Optic neuritis Study Group (1997) The 5-year risk of MS after optic neuritis. Neurology 49:1404-1413
38. O'Riordan J, Thompson A, Kingsley D, et al. (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNSA 10-year follow-up. Brain 121:495-503
39. Panitch H, Goodin D, Francis G, et al. (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE trial. Neurology 59:1496-1506
40. Poser CM, et al. (1983) New diagnostic criteria for multiple sclerosis. Guidelines for research protocols. Ann Neurol 13:227-230
41. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group and UBC MS/MRI Analysis Group (2001) PRISMS-4: Long-term efficacy of interferon beta-1 a in relapsing MS. Neurology 56:1628-1636
42. Report of the quality standards subcommittee of the American Academy of Neurology (1994) Practise advisory on selection of patients with multiple sclerosis for treatment with Betaseron®. Neurology 44:1537-1540
43. Rieckmann P, Toyka KV, Austrian-German-Swiss multiple sclerosis therapy consensus group - MSTCG (1999) Escalating immunotherapy of multiple sclerosis. Eur Neurol 42:121-127
44. Sellebjerg F, Nielsen H, Frederiksen J, Diesen J (1999) A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 52:1479-1484
45. Sorensen PS (2001) ESIMS. European Charcot Foundation; Venice, 10-21, (Abstract)
46. Sorensen PS, Fazekas F, Lee M (2002) Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9:557-563
47. Sorensen PS, Ross C, Clemmesen M, et al. (2003) Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184-1181
48. Stangel M, Boegner F, Klatt C, Hofmeister C, Seyfert S (2000) Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 68: 89-92
49. Sudlow C, Counsell C (2003) Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. Br Med J 326:388-392
50. The Once Weekly Interferon for MS Study Group - OWIMS (1999) OWIMS - Evidence of interferon beta-1a dose response in relapsing-remitting multiple sclerosis. Neurology 53:679-686
51. Tintore M, Rovira A, Martinez M, et al. (2002) Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 21:702-706
52. Tintore M, Rovira A, Rio J, et al. (2003) New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 60:27-30
53. Weinshenker B, O'Brien P, Petterson T, et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878-886
54. Wiendl H, Hohlfeld R (2002) Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16:183-200
55. Wolinsky JS, Toyka KV, Kappos L, Grossberg SE (2003) Interferon-beta antibodies: implications for the treatment of MS. Lancet Neurol 2:528
56. Yudkin PL, Ellison GW, Ghezzi A (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338: 1051-1055
57. Zivadinov R, Rudick R, De Masi R, et al. (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57: 1239-1247